Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
IL-2 is used systemically for cancer therapy but it is associated with severe toxicity. Here, the authors design a recombinant vaccinia virus expressing membrane-bound IL-2 that shows therapeutic efficacy alone or in combination with checkpoint inhibitors in colon cancer-bearing mice.
Guardado en:
Autores principales: | , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf8c62b2e7b9492694731295e94b4d6e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|